Statins in the 21st century: End of the simple story?

Expert Opinion on Investigational Drugs

Volumn 10, Issue 9, 2001, Pages 1755-1766

  Doggrell, S A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

Clinical trials; Lipid lowering; Mechanisms; Statins

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID A PROTEIN; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUINDOSTATIN; HYALURONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; LECTIN; LISINOPRIL; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEVINOLIN; PLACEBO; PRAVASTATIN; SELECTIN; SIMVASTATIN;

ANGIOCARDIOGRAPHY; ANGIOPLASTY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; DOUBLE BLIND PROCEDURE; FEMALE; FLOW KINETICS; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; STROKE; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM;

CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 0034846186     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.9.1755     Document Type: Article

References (74)

1. The evolving role of statins in the management of atherosclerosis
2. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel JJ)
3. An evidence-based assessment of the NCEP Adult Treatment Panel II Guidelines. National Cholesterol Education Program
4. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S)
5. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)
6. Reduced coronary events in simvastatin-treated patient with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study
7. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
9. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels; Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial
10. Reduction of stroke incidence with myocardial infarction after pravastatin; The Cholesterol and Recurrent Events (CARE) Study
11. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
13. Effects of lowering average or below-average cholesterol on the progression of carotid atherosclerosis; Results of the LIPID atherosclerosis substudy
14. Pravastatin therapy and the risk of stroke
15. Effects of pravastatin in 3260 patients with unstable angina: Results from the LIPID study
16. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia
17. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
18. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
19. Westendorf: Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
20. Reductase inhibitor monotherapy and stroke prevention
21. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
22. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)
23. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography
24. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women
25. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis
26. Effect of simvastatin on coronary atheroma: The Muticentre Anti-Atheroma Study (MAAS)
27. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC I investigation
28. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symtomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
29. The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS)
30. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
31. The effect of aggressive lowering of low-density lipoprotein cholesterol and low-dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts
32. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary bypass graft clinical trial. Post CABG Trial Investigators
33. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial
34. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril coronary atherosclerosis trial
35. Prevention of restenosis by lovastatin after successful angioplasty
36. Lack of effect of lovastatin on restenosis after coronary angioplasty
37. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial
38. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty
39. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial
40. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hyercholesterolemia
41. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
42. Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly disease coronary arteries
43. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
44. Cholesterol lowering with pravastatin improves resistance artery endothelial function: Report of six subjects with normal coronary arteriograms
45. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days
46. Effect of simvastatin on ejection fraction in cardiac transplant recipients
47. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension
48. Abnormalities of blood rheology in familial hypercholesterolemia: Effect of treatment
49. Effect of atorvastatin on plasma fibrinogen
50. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients
51. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia
52. Hyperlipidemia and coronary disease. Correction of increased thrombogenic potential with cholesterol reduction
53. Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect
54. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia
55. Statins and cardiovascular disease: The multiple effects of lipid-lowering therapy by statins
56. Hypercoagulable state in hypercholerolemic subjects assessed by platelet-dependent thrombin generation: In vitro effect of cerivastatin
57. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
58. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients
59. Effect of simvastatin therapy on paroxonase activity and related lipoproteins in familial hypercholesterolemic patients
60. Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men
61. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
62. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
63. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
64. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
65. Production of C-reactive protein and risk of coronary events in stable and unstable angina
66. The prognostic value of C-reactive protein and serum amyloid protein in severe unstable angina
67. Long-term effects of pravastatin on plasma concentration of C-reactive protein
68. The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design
69. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
70. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
71. Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes
72. Leukocyte-Endothelial adhesion molecules
73. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
74. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)